The research is focused on developing a drug that enables patients to benefit from the medicinal benefits of THC without experiencing its inherit psychoactive properties.
This first-of-its-kind process enables the company to produce cGMP-compliant, pure THC molecules to be used as the active pharmaceutical ingredient in products currently undergoing research for multiple conditions.
The trial is designed to assess the time-to-relief in patients suffering from severe pain.
Though almost half of oncologists surveyed recommend medical marijuana clinically, less than a third feel equipped with enough knowledge to make such recommendations.
While cannabis flower characterized the market in the early years, cannabis extracts have become increasingly popular and eclipsed cannabis flower sales this year.